Leon-nanodrugs and Instillo work together to tackle formulations issues

MJR technology offers reformulation options that can lead to a superior profile for an API.

It is estimated that over 60% of pharmaceutical APIs are poorly soluble in water. Leon’s MJR technology offers reformulation options that not only address this issue, but can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability, improving onset of action, etc. The one-step, bottom up, continuous precipitation process approach of the MJR technology is highly cost effective and easily scalable.

Dr Theron E. Odlaug, CEO of leon-nanodrugs and the US subsidiary explains: “The vision of leon- nanodrugs is to be recognized as a global leader in nanotechnology-formulated pharmaceuticals through contract services and co-development partnerships. Through the unique attributes of our MJR technology, our goal is to generate added value to both established molecules and novel NCEs. We will be seeking a commercial partner for the product once we have shown bioequivalence.”

Dr Bernd Baumstümmler, CEO of Instillo states: “Instillo Group bring experts from different areas together for the ultimate support for our customers in a range of pharmaceutical services from development through registration to commercialization by the companies MJR PharmJet and Quasaar. Quasaar takes over the GMP-relevant aspects of drug and formulation development and brings the products forward in the path of commercialization.”